Mustang Bio Stock Price, News & Analysis

Mustang Bio, Inc. (NASDAQ: MBIO) announced that clinical trial data for its PSCA CAR T-cell therapy, MB-105, has been selected for presentation at the 2022 ASCO Genitourinary Cancers Symposium. The Phase 1 trial aims to assess dose limiting toxicity and preliminary efficacy in patients with PSCA-positive mCRPC. So far, 12 patients have been treated, and results indicate the therapy is feasible with a potential anti-tumor effect. Notably, no dose limiting toxicities were observed at the 100M cell dose, while some grade 3 non-infective cystitis occurred at higher doses.

Mustang Bio (NASDAQ: MBIO) has been awarded the Bronze winner for the Central region in the Eighteenth Annual Team Massachusetts Economic Impact Awards, recognizing its significant contributions to the local economy. The company achieved job growth by adding 56 new positions since January 2020 and maintains a diverse workforce with 53% women and 26% minority employees. Mustang invested $2.5 million in a 6,000 square-foot facility expansion aimed at scaling its manufacturing of cell and gene therapies. The award ceremony is scheduled for April 7, 2022.

Mustang Bio, Inc. (NASDAQ: MBIO) announced a hold from the FDA on its IND application for MB-207, a lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID). The hold is pending CMC clearance and follows an IND submission in December 2021. Mustang's MB-107, another therapy for XSCID, is in a Phase 1/2 trial for newly diagnosed infants. If approved, both therapies could receive a rare pediatric disease voucher. Mustang remains committed to advancing its clinical trials for XSCID treatments.

Mustang Bio (NASDAQ: MBIO) announced interim Phase 1/2 data on its CD20-targeted CAR T cell therapy, MB-106, for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. This data will be presented at the 2022 Tandem Meetings in Salt Lake City from February 2-6. CEO Manuel Litchman highlighted MB-106's promising efficacy and safety profile, aiming for further updates and a multicenter trial under Mustang's IND within the quarter. MB-106 is developed in collaboration with Fred Hutchinson Cancer Research Center.

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company, announced participation in three virtual investor conferences in January 2022. The events include the 11th Annual LifeSci Partners Corporate Access Event (Jan 5-7), H.C. Wainwright Virtual BioConnect Conference (presentation available Jan 10), and B. Riley Securities’ Virtual Oncology Conference (fireside chat on Jan 28). Webcasts of the presentations will be accessible on Mustang's website for approximately 30 days post-event. Mustang aims to develop cell and gene therapies for various cancers and rare diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its inclusion in the NASDAQ Biotechnology Index® effective December 20, 2021. The NBI tracks biotechnology and pharmaceutical companies listed on NASDAQ and is re-ranked annually based on specific eligibility criteria, such as market capitalization and trading volume. This addition may enhance Mustang's visibility and attract greater investor interest, potentially impacting its stock performance positively. Mustang focuses on cell and gene therapies for various cancers and genetic diseases, advancing partnerships with leading medical institutions.

Mustang Bio, Inc. (NASDAQ: MBIO) announced promising results from its ongoing Phase 1/2 trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The trial demonstrated a significant overall response rate of 95% and a complete response rate of 65%, alongside a favorable safety profile. The data was presented at the 63rd ASH Annual Meeting. Mustang plans to conduct further trials under an IND approved by the FDA, with patient enrollment starting early next year.

Mustang Bio, a clinical-stage biopharmaceutical company focused on cell and gene therapies, will host a webinar on December 16, 2021, at 2:30 p.m. ET. The event will present interim results from the Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. Dr. Mazyar Shadman from Fred Hutch will lead the discussion, with a Q&A session to follow. Mustang's IND was accepted by the FDA to initiate this trial, aimed at evaluating the safety and efficacy of MB-106 in patients with relapsed or refractory conditions.

Mustang Bio, Inc. (NASDAQ: MBIO) reported Q3 financial results, showing a net loss of $17.0 million ($0.19/share), up from $13.0 million ($0.23/share) a year earlier. Cash and equivalents totaled $121.9 million, down from $130.9 million in Q2 2021. Significant advancements include promising data from MB-106 CD20-targeted CAR T therapy, achieving a 94% overall response rate. The company secured a $2 million grant from the NCI to support MB-106 and received PRIME designation for MB-107 from the EMA. Upcoming presentations and trials are anticipated to further validate their therapies.